Greenland Mines Ltd. (NASDAQ: GRML) announced that Innovation, Science and Economic Development Canada has granted a patent covering technology exclusively licensed by the company for Klotho-based gene therapies targeting cognition, memory and neurodegenerative diseases. The patent protects the use of the secreted Klotho (“s-KL”) RNA splice variant in genetic therapies and includes 42 claims covering its synthesis, delivery methods and potential application across multiple neurological disorders, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis.
The company said the Canadian patent expands its intellectual property portfolio for Klotho-based therapeutics and complements previously issued patents in the United States, China and Europe. Greenland Mines added that process development and manufacturing for lead candidate KLTO-101 is scheduled to begin in August 2026, while KLTO-202 has advanced to GMP manufacturing as the company prepares for regulatory interactions later this year.
This news matters because it strengthens Greenland Mines’ position in the competitive landscape of gene therapy for neurodegenerative diseases. The patent portfolio now spans key global markets, providing a foundation for potential commercialization. For leaders in business and technology, this development signals the company’s commitment to building a multi-asset platform with exposure to both rare earth materials and midstream processing opportunities, while advancing its broader North Atlantic Critical Metals Corridor vision linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The implications for the industry are significant: neurodegenerative diseases represent a major unmet medical need, with limited treatment options. Klotho gene therapy could offer a novel approach to addressing cognitive decline and motor neuron diseases. If successful, KLTO-101 and KLTO-202 could transform the standard of care for conditions like ALS and Alzheimer’s disease. For investors and stakeholders, the expanded IP protection reduces risk and enhances the value proposition of the biotech division.
To view the full press release, visit https://ibn.fm/x2pHA.
